NCT05501418View on ClinicalTrials.gov

Evaluate the Safety and Efficacy of Allogeneic Umbilical Cord Mesenchymal Stem Cells in Patients With COVID-19

PHASE1/PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

75

Participants

Timeline

Start Date

August 5, 2020

Primary Completion Date

December 31, 2025

Study Completion Date

December 31, 2025

Conditions
COVID-19 Infection
Interventions
BIOLOGICAL

Allogeneic umbilical cord mesenchymal stem cells

UMSC01 cells will be IV infusion with 12 months of follow up after treatment.

BIOLOGICAL

Controlled normal saline

Normal saline will be IV infusion with 12 months of follow up after treatment.

Trial Locations (1)

404

China Medical University Hospital, Taichung

All Listed Sponsors
lead

Ever Supreme Bio Technology Co., Ltd.

INDUSTRY